Loading data for CELZ — first visit, this takes a few seconds.

Alerta

Creative Medical Technolo... (CELZ)

NasdaqCM: CELZ · Precio en tiempo real · USD

1.21

-0.10 (-7.63%)

Al cierre: Aug 28, 2026, 8:00 PM

1.14

-0.20%

Fuera de horario: 6:17 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-7.63% (1D)

No hay datos disponibles

Precio de compra	0.89
Capitalización de mercado	7.52M
Ingresos (TTM)	3K
Beneficio neto (TTM)	-6.04M
	1.94
	-2.05
	n/a
	-1.3
P/B (TTM)	0.86
P/S (TTM)	2505.17
Fecha de resultados	n/a

Precio de venta	1.54
Volumen	383,992
Volumen medio (20D)	9,654,080
Abierto	1.29
Anterior Cerrar	1.31
Rango del día	1.19 - 1.29
Rango de 52 semanas	0.62 - 6.25
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de CELZ

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Nov 6, 2015

Empleados 4

Bolsa de Valores NasdaqCM

Símbolo bursátil CELZ

Sitio web https://www.creativemedicaltechnology.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Creative Medical Technology fueron 6K, una disminución de -45.45% en comparación con 11K del año anterior. Las ganancias fueron -6M, un aumento de 9.13%.

Estados financieros

Sorpresa de resultados

Creative Medical Technology ha publicado sus resultados trimestrales en Aug 7, 2026:

Ingresos de $0 falla las estimaciones por $0, con -100.00% Disminución interanual.
EPS de -0.41 falla las estimaciones por -0.02, con 14.58% Crecimiento interanual.

Noticias

3 semanas hace · InvestorsHub

Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy

The new patent allowance expands intellectual property protection around Creative Medical’s diabetes pipeline while supporting its strategy across cell-based and cell-free immunotherapy platforms. Key...

2 meses hace · Stocktwits

These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism?

Creative Medical Technology, Baiya International Group, and GD Culture Group shares slumped to their 52-week lows amid divestiture and fundraising updates.

2 meses hace · Proactive

Creative Medical Technology opens nationwide burn-pit data registry

Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has moved Project PHOENIX into a nationwide virtual data-collection phase, opening enrollment for a regulatory-approved registry that the company...

4 meses hace · Simply Wall St.

Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long

Creative Medical Technology Holdings, Inc. ( NASDAQ:CELZ ) is possibly approaching a major achievement in its business...

9 meses hace · Zacks

Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now

Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings ...

Página 1 de 2